Pharma-Bio Serv, Inc. (PBSV) Fair Value 2026

PBSV · Health Information Services ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 3 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-10-07, Pharma-Bio Serv, Inc. (PBSV) trades at $0.46, versus a $0.28 median fair value across its 3 active models — 38.7% below the current price. QOC: 6.0/10. Value Trap Risk: 26/100 (LOW). 3/13 models active.

Key Facts

Ticker
PBSV
Price
$0.46
Quality Score
6.0/10
Value Trap Risk
26/100
Models Active
3/13
Last Updated
Strength: CUCE Ensemble suggests +286.4% upside with 3% confidence
Risk: Majority of models suggest overvaluation

Is Pharma-Bio Serv, Inc. (PBSV) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Pharma-Bio Serv, Inc. (PBSV) appears overvalued as of : the median of 3 independent fair value estimates is $0.28, 38.7% below the current price of $0.46. Estimates range from $0.14 to $1.78. PBSV scores 6.0/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. PBSV’s -38.7% gap is wider than that market norm, and the Health Information Services sector median is +1.2%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Pharma-Bio Serv, Inc. Stock in 2026? →

What Fair Value Does Each Model Give PBSV?

3 Intrinsic Value Models vs. Current Price ($0.46)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $1.78 +286.4%
Intrinsic · High Conviction
 $0.14 -69.7%
Asset-Based · High Conviction
 $0.28 -38.7%

All Models Active

All 3 models are displayed above.

What Is PBSV's Fair Value Range?

Spread across 3 independent models · $0.14 to $1.78

CirclFi's 3 active models place Pharma-Bio Serv, Inc. (PBSV) between $0.14 and $1.78 per share, a spread of 581% of the median. The median of that range — $0.28 — is the fair value CirclFi publishes for PBSV, against a current price of $0.46.

Low · ML-RIVHigh · CUCE
$0.14median $0.28$1.78
Where the range comes from
Most bearish modelML Residual Income$0.14
Most bullish modelCUCE$1.78
Model agreement1 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for PBSV. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on PBSV, not a CirclFi price target. How each model works →

What Is Pharma-Bio Serv, Inc. (PBSV) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Pharma-Bio Serv, Inc. at its current price of $0.46. The median intrinsic value is estimated at $0.28 (-38.7% vs price), with 2 models flagging overvaluation risk. The most optimistic model, CUCE, places fair value at $1.78 (+286.4%), while ML-RIV — the most conservative — estimates $0.14 (-69.7%). This +356.1% gap reflects genuine analytical uncertainty about Pharma-Bio Serv, Inc.'s intrinsic worth.

What Do the Models Say About PBSV?

3 of 13 models are currently active for PBSV. Of these, 1 model suggests upside while 2 models suggest overvaluation. Taken together, their median fair value for PBSV is $0.28 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does PBSV Rank in Health Information Services?

Among 53 Health Information Services stocks, PBSV ranks #32 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

See all Most Undervalued Health Information Services Stocks →

Pharma-Bio Serv, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is PBSV a Value Trap?

CirclFi's Value Trap algorithm assigns PBSV a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Pharma-Bio Serv, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Pharma-Bio Serv, Inc. is rated at 6.0/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +356.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PBSV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PBSV's 3 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pharma-Bio Serv, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Health Information Services Stocks Should You Also Analyze?

11 related Health Information Services stocks with 13-model coverage

DRIODarioHealth Corp.QOC 6.0SOPHSOPHiA GENETICS SAQOC 5.9HTFLHeartflow, Inc.QOC 6.1EVHEvolent Health, Inc.QOC 5.9CRVWCareView Communications, Inc.QOC 6.2OMDAOmada Health, Inc.QOC 5.8VSEEVSee Health IncQOC 4.7SPOKSpok Holdings, Inc.QOC 8.6BTSGBrightSpring Health Services, Inc.QOC 7.2DOCSDoximity, Inc.QOC 9.6HQYHealthEquity, Inc.QOC 9.5

Read investment analysis: DRIO · SOPH · HTFL · EVH · CRVW · OMDA · VSEE · SPOK · BTSG · DOCS · HQY

Which Other Stocks Have a Similar Quality Score to PBSV?

7 companies across all industries closest to PBSV’s Quality of Company score of 6.0/10.

NUVBNuvation Bio Inc.QOC 6.0COMPCompass, Inc.QOC 6.0VUZIVuzix CorporationQOC 6.0COOKTraeger, Inc.QOC 6.0CABRCaring Brands, Inc.QOC 6.0PTNPalatin Technologies, Inc.QOC 5.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NUVB · COMP · VUZI · COOK · CABR · PTN · NVDA

Where Does PBSV Sit in CirclFi's Health Information Services Rankings?

PBSV is ranked against every other Health Information Services stock CirclFi covers in each of these screens.

See all Health Information Services stocks ranked →

What Else Do Investors Ask About Pharma-Bio Serv, Inc.’s Valuation?

What is Pharma-Bio Serv, Inc.'s intrinsic value in 2026?

CirclFi puts Pharma-Bio Serv, Inc. (PBSV)'s intrinsic value at $0.28 — the median of 3 independent model estimates as of 2026-10-07, ranging from $0.14 to $1.78. The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PBSV overvalued or undervalued right now?

At $0.46, 1 of 3 active models suggest PBSV may be undervalued, while 2 indicate potential overvaluation. The median of all 3 fair value estimates is $0.28, 38.7% below the current price of $0.46 — a consensus view that PBSV is overvalued. The assessment depends on which methodology best fits Pharma-Bio Serv, Inc.'s business model in Health Information Services.

What does a Quality of Company score of 6.0 mean for PBSV?

Pharma-Bio Serv, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PBSV?

CirclFi analyzes PBSV with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PBSV?

Of the 3 models currently active on PBSV, CUCE is the most bullish at $1.78 per share, and ML Residual Income is the most bearish at $0.14. CirclFi's published fair value for PBSV is the median of that range, $0.28, not either extreme. The gap between the two ends equals 581% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is PBSV a value trap in 2026?

Pharma-Bio Serv, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Pharma-Bio Serv, Inc. (PBSV) has a median fair value of $0.28 — 38.7% below the current price of $0.46 — as of 2026-10-07.” Source: circlfi.com/stock/PBSV/ · Methodology
Primary sources for this PBSV valuation
  • Financial statements: Pharma-Bio Serv, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001304161) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PBSV as of ; valuations recomputed .